Actualités dans la gestion des syndromes coronariens aigus
Actualités dans la gestion des syndromes coronariens aigus Actualités dans la gestion des syndromes coronariens aigus
Primary Outcome Measures (ITT) Diff = -2.9% [-4.9,-0.8] RR = 0.76 [0.63,0.92] P NI ≤ 0.0001 sup = 0.006 P sup Diff = -3.3% [-4.0,-1.6] RR = 0.60 [0.46,0.77] P NI ≤ 0.0001 sup ≤ 0.0001 P sup Diff = 0.0% [-1.6,1.5] RR = 0.99 [0.76,1.30] sup = 1.00 P sup 1° endpoint 1° endpoint *Not related to CABG **MACE = All cause death, reinfarction, ischemic TVR or stroke
1-Year Death or Reinfarction Death or MI (%) Number at risk Bivalirudin alone Heparin+GPIIb/IIIa 10 9 8 7 6 5 4 3 2 1 0 Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 4.5% 3.8% ∆ = 0.7% P=0.30 0 1 2 3 4 5 6 7 8 9 10 11 12 Time in Months HR [95%CI] = 0.77 [0.61, 0.98] P=0.04 1800 1670 1638 1617 1469 1802 1648 1617 1593 1431 8.5% 6.6% ∆ = 1.9%
- Page 1 and 2: Actualités s 2010 pour la prise en
- Page 3 and 4: douleur thoracique douleur persista
- Page 5 and 6: Recommandations Européennes (ESC 2
- Page 7 and 8: Le seul objectif du traitement de l
- Page 9 and 10: Reperfusion Therapy: Important Time
- Page 11 and 12: Stratégie de reperfusion d’un SC
- Page 13 and 14: Angiography after Fibrinolytic Ther
- Page 15 and 16: Fibrinolytic Therapy: Antithromboti
- Page 17 and 18: Thrombolysis vs primary PCI : 1 Yr
- Page 19 and 20: Peut on améliorer les délais % d
- Page 21 and 22: Décès, FV, choc cardiogénique à
- Page 23 and 24: Clopidogrel response variability fo
- Page 25 and 26: 15 TRITON study : Primary Endpoint
- Page 27: * Range ±7 7 days 3602 pts with ST
- Page 32 and 33: CK release during reperfusion CK re
- Page 34 and 35: Recommandations Européennes (ESC 2
- Page 36 and 37: Critères pour le bilan coronarogra
- Page 38 and 39: ACUITY - Primary Results UFH/Enoxap
- Page 40 and 41: 96-Hour Primary Efficacy Results Ro
- Page 42 and 43: ABOARD : Individual Ischemic Endpoi
1-Year Death or Reinfarction<br />
Death or MI (%)<br />
Number at risk<br />
Bivalirudin alone<br />
Heparin+GPIIb/IIIa<br />
10<br />
9<br />
8<br />
7<br />
6<br />
5<br />
4<br />
3<br />
2<br />
1<br />
0<br />
Bivalirudin alone (n=1800)<br />
Heparin + GPIIb/IIIa (n=1802)<br />
4.5%<br />
3.8%<br />
∆ = 0.7%<br />
P=0.30<br />
0 1 2 3 4 5 6 7 8 9 10 11 12<br />
Time in Months<br />
HR [95%CI] =<br />
0.77 [0.61, 0.98]<br />
P=0.04<br />
1800 1670 1638 1617 1469<br />
1802 1648 1617 1593 1431<br />
8.5%<br />
6.6%<br />
∆ = 1.9%
Change language